Economy Update – Baghdad
The General Company for the Medicines and Medical Supplies Industry in Samarra has unveiled its production program for February, with an estimated budget exceeding 3 billion dinars.
According to the company’s announcement, the production program for February 2025 is valued at over 3 billion and 25 million dinars. This budget will facilitate the supply of pharmaceutical products to the Ministry of Health and meet demands in the local market for various forms of medication, including tablets, ointments, powders, and liquid preparations.
Managing Director Al-Nuaimi indicated that employees across production and support departments have initiated the implementation of this month’s production plan. The program aligns with contracts established with the Iraqi Ministry of Health and the Specialized Marketing Agency, aiming to provide the pharmaceutical preparations produced by the company.
Furthermore, Al-Nuaimi noted that the production plan could expand, contingent on the availability of raw materials and other necessary supplies. It outlines the creation of an array of conventional and modern treatments aimed at addressing chronic diseases, alongside the production of anti-respiratory medications, cough suppressants, and pain relief products for diverse age demographics.
The production agenda also details the development of pediatric medication for the local market, including powders designed to treat indigestion, urinary issues, and dehydration. Additionally, the company plans to supply various anti-fungal ointments targeting a range of skin disorders.
For ongoing updates, subscribe to our channel.